Entolimod Shows Promise in Mice as Potential Treatment for Radiation Sickness
A biologic drug called entolimod has successfully passed safety testing in mice and is now advancing to a critical efficacy study focused on survival rates after radiation exposure. Designed to activate immune pathways linked to tissue recovery, the drug aims to treat acute radiation syndrome, particularly its gastrointestinal form, with results expected by early December. The research, funded by NIAID and conducted by AFRRI, will use animal data to support future FDA approval under the Animal Rule due to ethical constraints on human trials.
On October 28, 2026, Valion Bio announced that entolimod, a biologic drug developed to treat acute radiation syndrome (ARS), successfully passed safety testing in mice, paving the way for a follow-up efficacy study launched on October 30. The study, funded by the National Institute of Allergy and Infectious Diseases (NIAID) and conducted by the Armed Forces Radiobiology Research Institute (AFRRI), will assess entolimod’s ability to improve survival in mice exposed to partial-body radiation—specifically targeting the gastrointestinal form of ARS. The design includes shielding approximately 2.5% of each mouse’s bone marrow to isolate gastrointestinal effects from hematopoietic ones. Animals will receive a single dose of entolimod or saline 24 hours post-exposure and be monitored for 30 days, with survival as the primary endpoint; results are expected by early December. Entolimod activates Toll-like Receptor 5, a pathway linked to tissue recovery and immune modulation. Valion holds an exclusive license from Statera Biopharma and has received Fast Track and Orphan Drug designations from the FDA, signaling accelerated review pathways. The drug’s development is guided by the FDA’s Animal Rule, which permits approval based on animal data when human trials are ethically unfeasible due to the risks of radiation exposure.
The broader context includes prior work by AFRRI and NIAID in developing medical countermeasures for radiological threats, particularly in military and emergency res
Entolimod’s progress could significantly impact national security and public health preparedness for radiological incidents, such as nuclear accidents or terrorist attacks involving radiation dispersal devices. If proven effective, it may become a key component of stockpiled medical countermeasures, particularly for first responders and military personnel in high-risk zones. The drug’s development under the FDA’s Animal Rule reflects a broader trend in biodefense—where treatments for rare but catastrophic conditions rely on animal data due to ethical limitations. A comparable precedent is the approval of bexarotene for radiation-induced skin injury, which also relied on animal studies. The success of entolimod may encourage further investment in similar biologics targeting acute syndromes with no viable human testing pathways. However, its real-world impact depends on timely regulatory approval and integration into emergency response protocols. Market-wise, Valion Bio could see increas